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Despite the recent advances in the development of antitumor therapies, the prognosis for
patients with malignant gliomas remains dismal. Therapy with tumor-selective viruses is
emerging as a treatment option for this devastating disease. In this study we characterize
the anti-glioma effect of VCN-01, an improved hyaluronidase-armed pRB-pathway-selec-
tive oncolytic adenovirus that has proven safe and effective in the treatment of several solid
tumors. VCN-01 displayed a significant cytotoxic effect on glioma cells in vitro. In vivo, in
two different orthotopic glioma models, a single intra-tumoral administration of VCN-01
increased overall survival significantly and led to long-term survivors free of disease.
Introduction
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults [1]. Mul-
timodal treatment with surgery, radiotherapy, and chemotherapy extends mean survival by
only a few months [2] whilst the overall survival after recurrence ranges from 3 to 9 months
[3]. Therefore, the need for new therapeutic strategies is evident.
The use of oncolytic adenoviruses in tumour treatment is attractive because these viruses
can be produced in high titers, do not integrate into the host chromosome, have a wide tro-
pism, and possess a lytic life cycle that can be exploited for oncolysis [4]. Several selective onco-
lytic adenoviruses have shown promising results in the treatment of GBM in the preclinical
setting [5–8]. However, these viruses encounter a major hurdle which is the distribution within
the tumor due to physical limitations. They face transport barriers in the tumor interstitium,
due to their size (90–100 nm), much larger than chemotherapeutic drugs and that impairs opti-
mal distribution in solid tumors. The main sources of physical resistance to virus (and drug)
transport are the extracellular matrix (ECM) and interstitial fluid, both of which are abundant
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in solid tumors. Of relevance for this work, the high-molecular-weight glycosaminoglycan,
hyaluronic acid (HA), makes up a significant portion of the brain extracellular matrix [9,10]
The current study investigates the antiglioma effect adenovirus VCN-01, which is a modi-
fied virus based on the ICOVIR platform [11]. We previously showed that ICOVIR-5, a previ-
ous version of VCN-01, in which the control of E1A is under an E2F-1 promoter insulated
with the myotonic dystrophy locus insulator showed a safe toxicity profile and a robust anti-
glioma effect [12,13]. The modifications incorporated in VCN-01 are; a selective replication
depending on pRB pathway deregulation (for tumor selectivity), a retargeting modification
RGDK in the fiber shaft binding (for tumor targeting) and the expression of a modified hyal-
uronidase (to break down the extracellular matrix). Previously, it has been shown that VCN-01
induces a potent and selective replication profile when delivered systemically, and they demon-
strate that the modifications described above improved antitumor efficacy while maintaining a
safe toxicity profile [14]. In this work we seek to characterize the antiglioma effect in vivo and
in vitro of the oncolytic adenovirus VCN-01. VCN-01 showed a potent oncolytic effect in vitro
against a panel of cell lines. Of importance, treatment of two different in vivo orthotopic glioma
models with VCN-01 resulted in a significant increase in overall survival and in the number of
long-term survivors. Overall, these results encourage further development of VCN-01 against
malignant gliomas.
Materials and Methods
Cell lines and culture conditions
Glioma cell lines U87MG, A172, T98G, U251MG, U373MG and SNB19 were obtained from
the American Type Culture Collection (Manassas, VA, USA). Cell lines were maintained in
DMEM/F12 (1:1, v/v) (Gibco, Life Technologies, NY, USA) supplemented with 10% fetal
bovine serum in a humidified atmosphere containing 5% CO2 at 37°C. The adult glioma brain
tumor stem cell (BTSC lines GSC23, GSC11 were kindly provided by Dr. Lang (Department of
Neurosurgery; MD Anderson Cancer Center, USA). BTSCs were cultured as neurospheres.
The neurospheres were maintained in Dulbecco's modified Eagle/F12 medium (1:1, vol/vol)
(Thermo Fisher Scientific Inc, Waltham, MA) supplemented with B27 (Thermo Fisher Scien-
tific Inc, Waltham, MA), basic Fibroblast Growth Factor and Epidermal Growth Factor (20 ng/
mL Sigma-Aldrich, St Louis, MO).
Cell viability assay
Cells were seeded in 96-well plates at a density of 1x103 cells per well. Cells were infected with
VCN-01 on the same day as seeding. VCN-01 construction was carried out as described previ-
ously [14]. MOI ranged from 1 to 250. Cell viability was assessed five days later using the MTT
assay (Sigma-Aldrich, St. Louis, MO, USA) as described by Mosmann [15]. Dose–response
curves were analyzed using CalcuSyn Software (Biosoft, Cambridge, UK). IC50 is the median-
effective dose, that is, the dose that causes 50% of cells to be affected, which, in this case, is
equivalent to the dose that results in 50% survival.
Quantitative RT-PCR of mRNA levels
Quantitative RT-PCR was performed with ABI Prism-7500 (Applied Biosystems, Foster City,
CA, USA). The primers used for detection of hyaluronidase PH20 and Fiber mRNA transcripts
were:
• PH20 forward primer: 50- CTTAGTCTCACAGAGGCCAC-30
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• PH20 reverse primer: 50- CCAGGAGCAAGGAGTGTGTA-30
• Fiber forward primer: 50- ATTTGCCACATCCTCTTACAC -30
• Fiber reverse primer: 50 CAAACGCTGTTGGATTTATG -30
The cycling conditions for PCR were one cycle of 10 minutes at 95°C followed by 15s at
95°C, 1 minute at 60°C for 40 cycles. To determine relative gene expression, the comparative
threshold cycle (CT) method was used [16].
Western Blot analysis
Whole-cell lysate protein samples were resolved by SDS-PAGE, electro-blotted to a nitrocellu-
lose membrane (Bio-Rad, Hercules, CA, USA) and incubated with the following antibodies:
rabbit anti-E1A (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mouse anti-Fiber
(Thermo Scientific, MA, USA) and GRB2 (Santa Cruz Biotechnology, CA, USA).
Viral replication assays
Cell cultures were grown to 60–80% confluence in 24-well plates and subsequently infected at
an MOI that allowed at least 80% infectivity. On day 4 after infection cells and medium were
harvested and freeze–thawed three times. Viral titers in cell extracts were determined according
to an anti-hexon staining-based method [17].
Animal studies
In order to assess the antiglioma effect of VCN-01 in vivo we used two different glioma mouse
models. The first one is the well-established U87 MGmodel. The other model uses the BTSC
GSC23 cell line, which develops infiltrative and diffuse tumors that reflect the phenotype of gli-
omas in human patients.
Ethical approval for animal studies was granted by the Animal Ethical Committee of the
University of Navarra (CEEA; Comité Etico de Experimentación Animal under the protocol
number CEEA/069-13). All animal studies were done in the veterinary facilities of the
Center for Applied Medical Research in accordance with institutional, regional, and
national laws and ethical guidelines for experimental animal care. The animals were moni-
tored on daily basis and were euthanized when they demonstrate moribund behavior
including: slight head tilt, hemiparesis, hunched posture, scleral edema, inability to access
food/water, weight loss >20% of baseline, and excessive tumor burden as indicated by dom-
ing of cranium >0.5 cm, or if show signs of lower extremity weakness. The animals were sac-
rificed with CO2 inhalation. To minimize suffering of the animals, ketamine/xylazine or
buprenorphine was given for signs of pain, eye wincing, hunched state with front limbs over
the head.
Nude (nu/nu) mice were obtained from Taconic Farms Inc. U87 MG (5 × 105) and GSC23
cells (3 × 105) were engrafted into the caudate nucleus of athymic mice by means of the guide-
screw system described by [18]. On the third day after implantation of tumour cells, tumours
were injected with 5-μL of PBS, VCN-01 inactivated with UV light or VCN-01 solution: 10
mice received PBS, 10 mice received VCN-01 at 1×108 pfu/mouse previously inactivated with
UV (UVi), 10 mice received VCN-01 at a concentration of 1 × 107 pfu/mouse, and 10 mice
received VCN-01 at 1×108 pfu/mouse).
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Immunohistochemical analysis
Tumor xenografts and paraffin-embedded sections of mouse tumors were treated goat anti-
hexon antibody (Chemicon, CA, USA). For immunohistochemical staining, Vectastain ABC
kits (Vector Laboratories, CA, USA) were used according to the manufacturer's instructions.
Statistical analysis
For the in vitro experiments, data are expressed as mean ± SD, and comparisons were by the
two-tailed Student t test. The in vivo cytopathic effect of VCN-01 on human glioma xenografts
was assessed by plotting survival curves according to the Kaplan-Meier method. Survival in dif-
ferent treatment groups was compared using the log-rank test.
Results
VCN-01 exerts a potent antitumor effect in established and brain tumor
stem cell lines
To examine the antiglioma effect of the oncolytic adenovirus VCN-01 we performed viability
assays in a battery of established glioma cell lines (U87-MG, A172, T98G, U251-MG, U373,
and SNB19) and brain tumor stem cells (BTSC, GSC23, and NSC11) and also in the murine gli-
oma GL261. We choose the GL261 as a possible resistant cell line since adenovirus replication
is compromised in murine cell lines. All the glioma cell lines tested were susceptible to the cyto-
toxic effect of VCN-01. MOI IC50 ranged from 0.88±0.12 to 213±18. U87-MG was the most
sensitive cell line, and GSC23 the most resistant (Fig 1). As expected BTSC lines were more
resistant than established glioma cell lines at a similar or higher level than the virus resistant
GL261 cell line. Dose-response cytotoxicity was observed in all cell lines.
VCN-01 replicates efficiently in vitro
Replication was assessed by characterization of the expression of early and late adenoviral pro-
teins. E1A is expressed immediately after infection and initiates the viral replication cycle [19].
Fiber is a protein component of the capsid, it is expressed late in the replication process, and it
is thereby indicative of an effective viral replication cycle. Cells were infected at either 1 or 10
MOIs and protein expression was assessed 48 hours later. We observed a robust and dose
dependent expression of both E1A and Fiber proteins in all the cell line tested (Fig 2A) except
in the GL261 cell line where, as expected, fiber expression was absent. In addition, we observed
E1A and Fiber expression differences amongst the cell lines used suggesting differences in the
susceptibility to the virus effect. Next, we were interested in assess whether the hyaluronidase
(PH20) protein was being efficiently expressed by VCN-01. Analyses of PH20 mRNA expres-
sion in all the cell lines used in this study (except GL261) showed a consistent mRNA expres-
sion that was virus-dose dependent (Fig 2B). The expression of PH20 mRNA correlated with
the expression of Fiber (Fig 2B), suggesting similar kinetics.
Finally, quantification of VCN-01 replication and comparison of replication in cells infected
with 1 MOI or 10 MOI indicated that VCN-01 replicated effectively in all the cell lines tested
(Fig 2C). Replication was less effective in the BTSC lines, GSC23 and GSC11. Viral replication
was up to ten-fold higher in cells infected at a MOI of ten as compared to those at a MOI of
one. We also assessed the replication of VCN-01 in GL261 cell line and as expected we did not
observed any replication even at the highest dose used (300 MOIs) when compared with the
control (VCN-01 infected cells at 300 MOIs at 4 hours) (Fig 2D).
In conjunction, these results indicate that the virus infects and replicates effectively in gli-
oma cell lines. Moreover, in vitro, the virus expresses PH-20.
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VCN-01 treatment results in a significant antitumor effect in two
orthotopic glioma models
Mice bearing U87 MG or GSC23 intracranial xenografts were given intratumorally a single
injection of PBS (control), VCN-01 inactivated with UV (VCN-UVi 1x 108 pfu/mouse) VCN-
01 (1x107 pfu/mouse) or VCN-01 (1x 108 pfu/mouse). The median survival for mice that
received PBS or the virus inactivated with UV was 34/32 and 63 days, for U87 MG and NSC-23
mice, respectively. In contrast, the median survival of mice treated with VCN-01 at 1x107 pfu
were 86 and 85.5 days, for U87 MG and GSC23 mice, respectively. All U87-MGmice injected
with PBS or UV-inactivated virus died by day 39, and all GSC23 mice injected with PBS or
UV-inactivated virus died by day 70. Meanwhile, 80% of mice (both models pooled) whose
tumours were injected with 1x108 pfu of VCN-01 were alive at 90 days (Fig 3A).
Hematoxylin and eosin (H&E) staining revealed large, aggressive tumours in PBS control
mice while mice that received 107 pfu VCN-01 had smaller tumours with extensive necrotic
areas surrounded by areas displaying prominent viral inclusion bodies suggestive of effective
Fig 1. VCN-01 exerts a potent antitumor effect in established and brain tumor stem cell lines. (A) Cell viability analyses of VCN-01 infected glioma cell
lines. Cell viability was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays five days after infection. Data are shown
as the percentage (mean ±SD) of cells alive after infection with VCN-01 at the indicated multiplicities of infection (MOIs) relative to cells infected with UV-
inactivated VCN-01 (control, equal to 100%).
doi:10.1371/journal.pone.0147211.g001
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Fig 2. VCN-01 replicates efficiently in glioma cell lines in vitro. (A) The expression amounts of Fiber and E1A proteins in human glioblastoma were
determined byWestern blot analysis. Note that the levels were viral dose-dependent in all the cell lines. (B) The expression of Fiber and PH20 mRNA in all
the cell lines were determined by real time PCR; expression of both genes was correlated, suggesting similar kinetics and dose-dependency. The cell lines
used were SNB19, T98G, U87 MG, A172, U373 MG, U251 MG, GSC23 and GSC11. (C) The quantification of VCN-01 viral replication in all the cell lines.
Human glioblastoma cells were infected with two dilutions of VCN-01 (1 MOI and 10 MOIs). The virus replicated up to ten-times better in the cells infected
Antiglioma Effect of VCN-01
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viral infection and replication (Fig 3B). These latter areas typically stained for hexon proteins
(Fig 3C). Immunohistochemical studies of the brains of long-term survivors (of both U87 MG
and GSC-23 mice) showed no evidence of residual tumor; there was no staining with anti-
hexon antibodies, indicating an absence of viral particles (Fig 3C). In addition, we assessed the
expression of hyaluronic acid in the different treatment groups and compare it with the expres-
sion of hexon. Brains from control animals showed a uniform hyaluronic acid staining
throughout the tumor and the brain. Meanwhile in VCN-01 treated animals we could observed
that in areas surrounding hexon staining there was less hyaluronic acid staining suggesting the
effect of the hyaluronidase enzyme (Fig 3D; representative images from GSC23 bearing mice).
In summary, a single intra-tumoral injection of VCN-01 resulted in significant improve-
ment in survival in two different mouse models for glioma. These data suggest that VCN-01
may be a promising therapeutic agent for glioma.
Discussion
GBM is an aggressive tumor whose progression current therapies only manage to delay by a
few months. In the preclinical glioma study reported here, we characterize the anti-tumor effect
of VCN-01, a new generation oncolytic adenovirus developed by genetic modification from the
ICOVIR platform [14]. We found VCN-01 to induce a potent antitumor effect in vitro and in
vivo, and we therefore consider this virus to be a promising potential treatment for gliomas.
VCN-01 replication is engineered to require the existence of free E2F and is therefore
dependent on pRB pathway deregulation. Overexpression of E2F1 protein and the activation
of E2F-responsive promoters have been reported, by our group and others, to occur in gliomas
[20,21] and consequently, VCN-01 replication is expected to proceed in glioma cells. This
expectation was confirmed in the current study.
Several years ago our group published results of a study into the antiglioma effect of a pre-
cursor of VCN-01, ICOVIR-5, which combines E1a transcriptional control by an insulated
form of the E2F promoter with the Delta24 mutation of E1a. ICOVIR-5 has also the Kozak
sequence at the E1a start codon, and this sequence is important to restore E1a expression and
viral replication to AdwtRGD levels in tumor cells. ICOVIR-5 proved to be a highly selective
vector in glioblastoma preclinical models [12] and non-toxic to the model animal when admin-
istered systemically [13]. The drawback, however, was that ICOVIR-5 was less potent than the
same adenovirus without the E2F promoter. In contrast, VCN-01 is not only a safe vector
when delivered systemically but has a significant antitumoral effect in different solid tumors
[14].
In the current in vivo study, we used two different tumour models: a U87MG-based model,
which is aggressive but does not reflect the infiltrative phenotype of GBM; and a GSC23 model,
which is a BTSC line and gives rise to extremely aggressive and invasive tumours. Even with
GSC23-derived tumours, VCN-01 demonstrated effective antitumor activity with a single
injection.
Our study does not compare VCN-01 with other viruses, such as ICOVIR-5, and therefore
it remains a matter of speculation whether the enhanced antitumor effect is due to the
improved infectivity plus the expression of a soluble hyaluronidase (PH20). Another consider-
ation not covered by our study is the effect of VCN-01 in an immunocompetent model. It has
with 10 MOIs, which demonstrates that the virus infected and replicated efficiently in glioblastoma cell lines in vitro. (D) The quantification of VCN-01 viral
replication in GL261 murine cell line. GL261 cells were infected with two dilutions of VCN-01 (100 MOI and 300 MOIs). As a control for the replication we used
cells infected with VCN-01 at 300 MOIs and collected 4 hours after infection, during this time the virus does not have time to replicate indicating the initial viral
particles.
doi:10.1371/journal.pone.0147211.g002
Antiglioma Effect of VCN-01
PLOS ONE | DOI:10.1371/journal.pone.0147211 January 25, 2016 7 / 10
Fig 3. VCN-01 treatment results in a significant antitumor effect in two different in vivo gliomamodels. (A) Kaplan-Meier survival curves for overall
survival in VCN-01 (107 pfu), VCN (108 pfu) and control (PBS)-treated athymic mice bearing U87 MG and GSC23 intracranial xenografts. Intracranial
implantation of U87 MG or GSC23 cells (day 0) was followed by one intratumoral injection (on day 3) of VCN-01 (107 pfu; n = 10), VCN-01 (108 pfu; n = 10),
VCN-01 108 pfu UV inactivated (VCN01-UVi; n = 10) or PBS (control; n = 10). The P values were determined by the log-rank test and represent a comparison
of survival of VCN-01–treated mice with that of mice treated with PBS. (B) Hematoxilin and eosin staining of cross sections of U87 MG or GSC23 xenografts
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been speculated that the antitumor effect of oncolytic viruses is due not only to the intrinsic
cytolytic effect of the virus but also to the triggering of an immune response against the virus
and in turn against the tumoral cells hosting that virus. In this respect, it is interesting to note
that hyaluronidase is known to be immunogenic [22–26].
In conclusion, in vitro, VCN-01 effectively infected cells and replicated in glioma cell lines,
significantly reducing tumor growth. In vivo, a single intra-tumoral injection of VCN-01
resulted in significant (P<0.0001) improvement in survival in two different mouse models for
glioma. These preclinical results suggest that VCN-01 warrants further study to evaluate its
potential in the treatment of malignant gliomas.
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